Algernon Pharmaceuticals EBITDA vs. Beta

AGNPF Stock  USD 0.05  0  8.70%   
Based on Algernon Pharmaceuticals' profitability indicators, Algernon Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Algernon Pharmaceuticals' ability to earn profits and add value for shareholders.
For Algernon Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Algernon Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Algernon Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Algernon Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Algernon Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Algernon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Algernon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Algernon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Algernon Pharmaceuticals Beta vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Algernon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Algernon Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Algernon Pharmaceuticals is number one stock in ebitda category among its peers. It is rated third in beta category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Algernon Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Algernon Beta vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Algernon Pharmaceuticals

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(6.02 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Algernon Pharmaceuticals

Beta

 = 

Covariance

Variance

 = 
0.32
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Algernon Beta Comparison

Algernon Pharmaceuticals is currently under evaluation in beta category among its peers.

Beta Analysis

As returns on the market increase, Algernon Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Algernon Pharmaceuticals is expected to be smaller as well.

Algernon Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Algernon Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Algernon Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Algernon Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Algernon Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada. Algernon Pharmaceuticals is traded on OTC Exchange in the United States.

Algernon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Algernon Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Algernon Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Algernon Pharmaceuticals' important profitability drivers and their relationship over time.

Use Algernon Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Algernon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Algernon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Algernon Pharmaceuticals Pair Trading

Algernon Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Algernon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Algernon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Algernon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Algernon Pharmaceuticals to buy it.
The correlation of Algernon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Algernon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Algernon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Algernon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Algernon Pharmaceuticals position

In addition to having Algernon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aircraft Thematic Idea Now

Aircraft
Aircraft Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Aircraft theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aircraft Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Algernon OTC Stock

To fully project Algernon Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Algernon Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Algernon Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Algernon Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Algernon Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Algernon Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Algernon Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.